(Q54560954)

31 May 2018

title

Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. (English)

1 reference

31 May 2018

author name string

Qiang Gao

1

1 reference

31 May 2018

Martin J W Meijer

2

1 reference

31 May 2018

Ulrike G Schlüter

3

1 reference

31 May 2018

Ruud A van Hogezand

4

1 reference

31 May 2018

Johanna M van der Zon

5

1 reference

31 May 2018

Marlies van den Berg

6

1 reference

31 May 2018

Wim van Duijn

7

1 reference

31 May 2018

Cornelis B H W Lamers

8

1 reference

31 May 2018

Hein W Verspaget

9

1 reference

31 May 2018

publication date

1 June 2007

1 reference

31 May 2018

Inflammatory Bowel Diseases

published in

1 reference

31 May 2018

volume

13

1 reference

31 May 2018

issue

6

1 reference

31 May 2018

page(s)

693-702

1 reference

31 May 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

cites work

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease.

21 January 2018

1 reference

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis

21 January 2018

1 reference

Matrix metalloproteinases: a tail of a frog that became a prince

21 January 2018

1 reference

Matrix metalloproteinases

21 January 2018

1 reference

Matrix metalloproteinase degradation of extracellular matrix: biological consequences

21 January 2018

1 reference

Matrix metalloproteinases: they're not just for matrix anymore!

21 January 2018

1 reference

Matrix metalloproteinases and angiogenesis

21 January 2018

1 reference

MMPs in the gut: inflammation hits the matrix

21 January 2018

1 reference

Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1.

21 January 2018

1 reference

Extracellular matrix remodelling: the role of matrix metalloproteinases

21 January 2018

1 reference

Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine

21 January 2018

1 reference

Expression of matrix metalloproteases in inflammatory bowel disease

21 January 2018

1 reference

Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis

21 January 2018

1 reference

Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease

21 January 2018

1 reference

Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease

21 January 2018

1 reference

Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease

21 January 2018

1 reference

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

21 January 2018

1 reference

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense

21 January 2018

1 reference

Paneth cell defensins and innate immunity of the small bowel

21 January 2018

1 reference

Interferons inhibit tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NF-kappa B.

21 January 2018

1 reference

Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP.

21 January 2018

1 reference

Role of matrix metalloproteinases in inflammatory bowel disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.20100

1 reference

31 May 2018

1 reference

31 May 2018